TIDMOXB
RNS Number : 1528N
Oxford Biomedica PLC
27 May 2022
Oxford Biomedica
Result of Annual General Meeting
Oxford, UK - 27 May 2022: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Company") , a leading gene and cell
therapy group, announces today that all resolutions proposed were
duly passed at its Annual General Meeting (AGM), held at 3pm on 27
May 2022 in Oxford. As proposed in the Notice of AGM, all
resolutions were decided by poll vote.
The full text of all the resolutions can be viewed in the Notice
of Meeting by visiting the Company's website at www.oxb.com
Copies of the document setting out the above resolutions passed
at the 2022 AGM have been submitted to the National Storage
Mechanism and will shortly be available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
On the Record Date (25 May 2022) there were 96,063,479 ordinary
shares of 50 pence each in issue, each carrying one vote per
share.
Votes
Votes at
For (incl. votes other Total
Resolution at the Chairman's proxy Votes Votes votes
discretion) Discretion Against Withheld* cast Result
Ordinary resolutions
------------------------------------------- ------------ ----------- ------------ ----------- -------
To receive
the Company's
Accounts,
the Reports
of the Directors
and Auditor
and the
Strategic
Report for
the year
ended 31
December
2021. 71,533,247 0 3,804 Passed
1 (99.99%) (0.01%) 907,786 71,537,051
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To receive
the Directors'
Remuneration
Report and
the Report
of the Auditor
on the Remuneration
Report for
the year
ended 31
December
2021. 57,808,878 0 13,801,220 Passed
2 (80.73%) (19.27%) 834,739 71,610,098
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To appoint
Dr. Michael
Hayden as
a Director. 62,539,719 0 9,295,954 Passed
3 (87.06%) (12.94%) 609,164 71,835,673
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To appoint
Catherine
Moukheibir
as a Director. 71,748,494 0 86,921 Passed
4 (99.88%) (0.12%) 609,422 71,835,415
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To appoint
Namrata
P. Patel
as a Director. 71,746,512 0 88,903 Passed
5 (99.88%) (0.12%) 609,422 71,835,415
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To reappoint
Dr. Roch
Doliveux
as a Director. 68,788,280 0 2,264,491 Passed
6 (96.81%) (3.19%) 1,392,066 71,052,771
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To reappoint
Professor
Dame Kay
Davies as
a Director. 69,259,453 0 2,575,962 Passed
7 (96.41%) (3.59%) 609,422 71,835,415
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To reappoint
Dr. Siyamak
Rasty as
a Director. 71,719,604 0 116,069 Passed
8 (99.84%) (0.16%) 609,164 71,835,673
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To reappoint
Stuart Paynter
as a Director. 71,206,012 0 629,661 Passed
9 (99.12%) (0.88%) 609,164 71,835,673
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To reappoint
Stuart Henderson
as a Director. 67,003,486 0 4,832,187 Passed
10 (93.27%) (6.73%) 609,164 71,835,673
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To reappoint
Dr. Heather
Preston
as a Director 64,708,975 0 7,126,698
11 (90.08%) (9.92%) 609,164 71,835,673 Passed
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To reappoint
Robert Ghenchev
as a Director. 71,526,110 0 309,305
12 (99.57%) (0.43%) 609,422 71,835,415 Passed
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To reappoint
KMPG LLP
as auditor. 71,831,890 7,494
13 (99.99%) 0 (0.01%) 605,453 71,839,384 Passed
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To authorise
the Directors
to agree
the remuneration
of the auditor. 71,832,849 6,921
14 (99.99%) 0 (0.01%) 605,067 71,839,770 Passed
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To authorise
the Directors
to allot
shares. 67,355,882 4,471,767
15 (93.77%) 0 (6.23%) 617,188 71,827,649 Passed
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
Special resolutions
------------------------------------------- ------------ ----------- ------------ ----------- -------
To authorise
the Directors
to disapply
pre-emption
rights. 70,888,310 0 937,061
16 (98.70%) (1.30%) 619,466 71,825,371 Passed
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To authorise
the Directors
to further
disapply
pre-emption
rights for
acquisitions
and specified
capital
investments. 70,922,796 0 903,407
17 (98.74%) (1.26%) 618,634 71,826,203 Passed
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
To permit
the Directors
to convene
general
meetings
(other than
annual general
meetings)
on not less
than 14
days' notice. 69,350,429 0 2,489,321 605,087
18 (96.53%) (3.47%) 71,839,750 Passed
--------------------- -------------------- ------------ ----------- ------------ ----------- -------
* A vote withheld is not a vote in law and is not counted
towards votes cast in respect of a resolution.
In addition, further to the announcements by the Company in
January and April, John Dawson has stepped down from the Company's
Board of Directors after more than thirteen years of service with
effect from the conclusion of today's AGM.
-Ends-
Enquiries:
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, Head of Investor Relations
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Matthew Neal / Matthew Cole
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector
specialist focused on delivering life changing therapies to
patients.
Oxford Biomedica plc and its subsidiaries (the Group) work
across key viral vector delivery systems including those based on
lentivirus, adeno-associated virus (AAV) and adenovirus, providing
innovative solutions to cell and gene therapy biotechnology and
biopharma companies for their process development, analytical
development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector(R)
platform, which the Group leverages to develop product candidates
in-house, before seeking partners to take the products into
clinical trials.
Oxford Biomedica is based across several locations and
headquartered in Oxfordshire, UK. In early 2022, the Group
established Oxford Biomedica Solutions, a new US based subsidiary
AAV manufacturing and innovation business, based near Boston,
US.
Oxford Biomedica employs more than 940 people. Further
information is available at www.oxb.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGSEUFMWEESEII
(END) Dow Jones Newswires
May 27, 2022 13:03 ET (17:03 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024